Illumina

“We are on the brink of a revolution,” says Tomasz K. Wojdacz. Researchers at PUM in Szczecin Poland are using the Illumina 5-base solution to develop more accurate, standardized approaches to tumor classification. By bringing methylation and genomic sequencing data together, they’re gaining a powerful new lens into disease biology—and accelerating precision medicine.  Read more: https://lnkd.in/ggv6uz_j Pomorski Uniwersytet Medyczny w Szczecinie

The Human Genome Project ended in 2003. For Illumina Chief Medical Officer Eric Green, M.D., Ph.D., it was the start of everything. In Episode 3 of The Sequence, he sits down with Cande Rogert, VP and Global Head of Advanced Science, to explore the competition and collaboration behind the project, the breakthroughs that followed, and what it could take to bring genomic medicine into healthcare systems around the world. This episode covers: 🔹 Why the completion of the Human Genome Project was a finish line – but also the start of everything 🔹 The real barriers to genomic access and why it isn't just about cost 🔹 The promise of genomics in cancer care and earlier disease detection 🔹 A future where genome sequencing is as routine as MRI scans and antibiotics 🎥 Watch or listen to the full episode now: https://lnkd.in/gSG-_2gK

Some genomic regions are still hard to resolve. Doing that work at scale can be even harder. Illumina TruPath™ Genome solution helps researchers get a clearer, more complete view of complex genetic variation using the short-read sequencing systems they already have. For Marcel Nelen, PhD, the biggest difference has been what TruPath enabled for his team. Illumina Connected Analytics, he said, “helped us tremendously to scale,” making it easier to work with more genomes and move research forward faster. See how Illumina TruPath can help simplify complex genome analysis: https://lnkd.in/gDQf_AnB #Genomics #NGS #Bioinformatics #PrecisionMedicine

Our CEO Jacob Thaysen joined CNBC this morning to discuss the company’s strong Q2 performance and continued momentum—from expanding clinical research to accelerating AI in life sciences.     See how Illumina is advancing its strategy and delivering powerful new solutions for customers. Watch the interview here: https://lnkd.in/gKn4mCkD

During the second quarter of 2026, we launched multiomic and software products, made powerful connections with academic partners, and expanded our footprint in oncology research. Here are some of the highlights 👇 🔶 Powering oncology research: We announced a new molecular residual disease research solution to enable more labs to advance MRD research. And, together with SPT Labtech, we launched the fireflyGO automation platform for targeted oncology research. 🔶 Scaling spatial transcriptomics: With the launch of StrataMap Spatial, researchers can access spatial biology at true single cell resolution for discovery without boundaries. DRAGEN software and Illumina Connected Multiomics provide powerful tools for spatial data analysis.  🔶 Advancing genomics for good: Our 2025 Corporate Responsibility Report demonstrated our ongoing commitment to increase equitable access to genomics, nurture our communities, and operate sustainably and responsibly. 🔶 Expanding our research partnerships: The University of Exeter announced an Illumina-funded effort to create an epigenetics database with methylation data from 60,000 UK Biobank samples. Additionally, we launched Beyond GiICS, a study of 400 unresolved childhood rare disease cases.  Learn more at https://www.illumina.com/ 

The first winners of the Illumina 5-Base for Cancer Research Grant Contest have been announced — recognized for scientific merit and their potential to advance cancer research through integrated genomic and epigenomic insights.    Following a large number of high-quality and competitive applications from researchers around the world, our advisory committee of Illumina scientists and Medical Affairs representatives selected three outstanding grant recipients. Congratulations to: 🏆 Alfonso Bellacosa, MD, PhD, Professor, Nuclear Dynamics and Cancer Program, Cancer Epigenetics Institute, Fox Chase Cancer Center (USA) 🏆 Jacob Blum, MD/PhD Candidate in the Cellular and Molecular Medicine Graduate Program at Johns Hopkins School of Medicine (USA) 🏆 Richard Tothill PhD, Associate Professor, The Collaborative Centre for Genomic Cancer Medicine - a joint venture between The University of Melbourne and Peter MacCallum Cancer Centre (Australia) We look forward to supporting their work with the Illumina 5‑base solution. Learn more about the Illumina 5‑Base for Cancer Research Grant Contest and this year’s recipients: https://lnkd.in/dWeCwKF2

Genes provide the blueprint, transcriptomics reveals the activity. Transcriptomics gives researchers a deeper understanding of how cells function, respond to disease, and react to treatment, taking their knowledge of genetics to the next level. In the latest installment of our Multiomics Explained series, we explore what transcriptomics is, how it works, and why it's becoming an essential tool in modern biological research. Read more: https://lnkd.in/gd45BaGu

What happens when whole-genome sequencing becomes a foundation of molecular pathology? At Michigan Medicine the answer was faster workflows, greater operational efficiency, expanded genomic insights, and more time for scientists and technologists to focus on innovation.  As demand for larger and more comprehensive panels grew, the team brought whole-genome sequencing in-house and transformed fragmented workflows into a streamlined model. Under the leadership of Annette Kim and her team, whole-genome sequencing serves as a backbone that can support a range of research needs. This team now spends less time on labor-intensive processes and iterative, gap-filling legacy tests. Whole-genome sequencing is powering research and saving resources in ways that many labs had not previously imagined.  🔗 Read how Michigan Medicine built their whole-genome foundation: https://lnkd.in/gXxgxyuE

Today is #GeneticTestingActionDay 🧬 A genetic diagnosis changed everything for Geraldine Bliss and her son Charles. Read more on how, through CureSHANK and Start Genetic, Geraldine is uniting advocates, patients, and partners, raising awareness about the power of early genetic testing to unlock answers, community, and a way forward 👇

A genetic diagnosis changed everything for Geraldine Bliss and her son, Charles, connecting them to a community and leading them to new opportunities in research and clinical trials.   Charles was diagnosed with Phelan-McDermid syndrome, a rare genetic disorder caused by a deletion or mutation of the SHANK3 gene. Today, he and his family are hopeful as a clinical trial evaluates a potential gene replacement therapy.   Through CureSHANK and Start Genetic Geraldine is uniting advocates, patients, and partners for Genetic Testing Action Day on July 25, raising awareness about the power of early genetic testing to unlock answers, community, and a way forward.   Read more about Geraldine and Charles's story: https://lnkd.in/gGdj9sVZ #GeneticTestingActionDay